SCHEMBL4676741

SCHEMBL4676741

O=C(C=C(O)c1nn[nH]n1)c1coc(Cc2ccc(F)cc2)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.33
PIN1 Q13526 1/20 0.33
IDH1 O75874 1/20 0.33
MMEL1 Q495T6 2/20 0.32
CES1 P23141 1/20 0.32
NCEH1 Q6PIU2 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
CXCR3 P49682 1/20 0.31
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ERCC5 P28715 1/20 0.31
FEN1 P39748 1/20 0.31
LTB4R2 Q9NPC1 1/20 0.31
MME P08473 1/20 0.31
GPR35 Q9HC97 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
LMNA P02545 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675580 0.90 IDH1 (0.42) PTGDR2PIN1IDH1MMEL1CES1
SCHEMBL4674709 0.90 IDH1 (0.33) PTGDR2IDH1MMEL1CES1NCEH1
SCHEMBL4672951 0.90 IDH1 (0.33) IDH1MMEL1CES1NCEH1ERCC5
SCHEMBL4672619 0.89 HCAR2 (0.39) PTGDR2PIN1IDH1MMEL1CES1
SCHEMBL4674370 0.89 XDH (0.38) IDH1CES1NCEH1ERCC5FEN1
SCHEMBL4672329 0.88 IDH1 (0.33) IDH1CES1NCEH1ERCC5FEN1
SCHEMBL4673591 0.87 MAPK8 (0.37) PTGDR2ALDH1A1HPGDCXCR3ERCC5
SCHEMBL4673698 0.84 PTGDR2 (0.36) PTGDR2MMEL1CES1NCEH1CXCR3
SCHEMBL4678236 0.83 LMNA (0.34) IDH1KDM4EALDH1A1HPGDPOLB
SCHEMBL4679601 0.83 MMEL1 (0.33) PTGDR2PIN1MMEL1CES1NCEH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTGDR2 4591/4885PIN1 323/4885IDH1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.